This is very good news for Merck, and consequently, the stock is up nicely, in the NASDAQ pre-market trading. Here's the presser:
. . . .Merck today announced that the pivotal Phase 3 KEYNOTE-189 trial investigating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with pemetrexed (Alimta®) and cisplatin or carboplatin, for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Based on an interim analysis conducted by the independent Data Monitoring Committee, treatment with KEYTRUDA in combination with pemetrexed plus platinum chemotherapy resulted in significantly longer OS and PFS than pemetrexed plus platinum chemotherapy alone. The safety profile of KEYTRUDA in this combination was consistent with that previously observed.
Results from KEYNOTE-189 will be presented at an upcoming medical meeting and submitted to regulatory authorities. . . .
Oh. And I cannot resist: Riot Blockchain is off another 12 per cent early this morning, on the NASDAQ. Hilarious.
Oddly, I was all done shoveling an hour ago -- but suddenly -- a solid white-out with sideways blasts is blowing through. . . should be a new few inches. So it goes. And we feature an ice-shelf on the masthead this early morning, in keeping with how much of the middle of the nation is feeling. Smile. Onward.
नमस्ते
3 comments:
off topic but relevant to other postings:
https://www.fiercebiotech.com/biotech/message-to-trump-alnylam-ceo-proud-to-be-a-shitholer
Hope your back is fine from shoveling that white stuff~~~
Thanks so much -- yes, my back is strong. . . my shoulders, broad. . . and I see it as an added part of the winter's regular workouts. . . smile.
I suppose more importantly -- I am still fairly. . . agog that 45 hasn't apologized for those remarks.
It is truly. . . despicable. And that CEO is right --on all counts!
Namaste. . .
And. . . Merck just posted Q4 2017 Keytruda sales that beat my guess-timate by $100 million -- I guessed $1.2 billion, in the above graphic -- and it was actually $1.3 billion.
Nice!
Post a Comment